Ph.D., Pharm.D., CPIC Co-PI/Director, St. Jude Children’s Research Hospital
Biography
Dr. Caudle is the Clinical Pharmacogenetics Implementation Consortium (CPIC) Co-PI and Director. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. To date, CPIC has published 26 gene-based clinical guidelines. In this position, Dr. Caudle oversees the CPIC guideline development process including the coordination of the guideline writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement. She also leads projects related to standardization of pharmacogenetic test results such as the CPIC term and CYP2D6 genotype to phenotype standardization projects. Dr. Caudle is based in the clinical pharmacogenetics group at St. Jude Children's Research Hospital. Dr. Caudle received her Pharm.D. and Ph.D. from The University of Tennessee Health Science Center and completed an ASHP-accredited PGY2 residency at Le Bonheur Children’s Research Hospital. She is also a board‐certified Pharmacotherapy Specialist.
Talk
The Clinical Pharmacogenetics Implementation Consortium (CPIC): From Evidence to Clinical Action
CPIC creates freely available, peer-reviewed, evidence-based, updatable, and detailed pharmacogenetic clinical practice guidelines. This talk will describe the process CPIC uses to evaluate evidence of pharmacogenomic associations for the interpretation of genetic test results to actionable prescribing recommendations.
Session Abstract – PMWC 2022 Silicon Valley
Track Chairs:
Philip Empey, UPitt
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.
- Keynote: The Future Of PGx
- Julie Johnson, University of Florida - Payment and Policy Landscape for PGx
- Sara Rogers, American Society of Pharmacovigilance
- PGx Research and Discovery
- Todd Skaar, Indiana University
- PGx Innovative Industry Solutions
- Jeffrey A. Shaman, Coriell Life Sciences
- Cassie Hajek, Helix
- Gillian Bell, Genome Medical
- Cindy Kosinski, 23andme
- Key Resources for PGx
- Kelly E. Caudle, St. Jude Children’s Research Hospital
- Michelle Whirl-Carillo, Stanford
- Clinical Laboratory PGx Considerations
- Ulrich Broeckel, MCW
- Stuart Scott, Stanford
- Victoria Pratt, Optum Genomics - Lessons from Frontline PGx Clinical Services
- Mark H. Dunnenberger, Northshore University HealthSystem
- Lucas Berenbrok, UPitt
- Sony Tuteja, UPenn
- Burns Blaxall, The Christ Hospital Health Network - Translational PGx Implementation Programs
- Philip Empey, UPitt
- Julie A. Johnson, Uinversity of Florida
- Laura Ramsey, Cincinnati Children's Hospital
- Nita A. Limdi, UAB
- PMWC Showcase
- Jose Estabil, Cipherome
